<!DOCTYPE html><html lang="en" class="__variable_6d343d __variable_49a339"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/_next/static/media/26d4368bf94c0ec4-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" href="/_next/static/media/36966cca54120369-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" as="image" href="/logo.svg" fetchPriority="high"/><link rel="stylesheet" href="/_next/static/css/115c5e9658b2e8f5.css" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/_next/static/chunks/webpack-27eef1fd2dac2dc4.js"/><script src="/_next/static/chunks/fd9d1056-561777fcc71322fd.js" async=""></script><script src="/_next/static/chunks/23-33936503cdfda89b.js" async=""></script><script src="/_next/static/chunks/main-app-9c6ab80fd9a4d8e3.js" async=""></script><script src="/_next/static/chunks/231-13cb1b3c6d429521.js" async=""></script><script src="/_next/static/chunks/app/asx/%5Bticker%5D/page-f6c15ab6b5482fb0.js" async=""></script><script src="/_next/static/chunks/410-0180f9689c5eaba7.js" async=""></script><script src="/_next/static/chunks/app/layout-cc68188960cc2107.js" async=""></script><link rel="icon" href="/logo.svg" type="image/svg+xml"/><title>EPN share price, analysis &amp; company profile - Epsilon Healthcare Limited | ASX Desk</title><meta name="description" content="Latest EPN share price overview, what Epsilon Healthcare Limited does, bull and bear cases, and AI-powered analysis for ASX investors."/><link rel="canonical" href="https://asxdesk.com/asx/EPN/"/><meta property="og:title" content="EPN share price, analysis &amp; company profile - Epsilon Healthcare Limited"/><meta property="og:description" content="Latest EPN share price overview, what Epsilon Healthcare Limited does, bull and bear cases, and AI-powered analysis for ASX investors."/><meta property="og:url" content="https://asxdesk.com/asx/EPN/"/><meta property="og:type" content="article"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="EPN share price, analysis &amp; company profile - Epsilon Healthcare Limited"/><meta name="twitter:description" content="Latest EPN share price overview, what Epsilon Healthcare Limited does, bull and bear cases, and AI-powered analysis for ASX investors."/><meta name="next-size-adjust"/><script src="/_next/static/chunks/polyfills-78c92fac7aa8fdd8.js" noModule=""></script></head><body class="min-h-screen bg-ink-900 text-slate-100"><div class="grid-glow min-h-screen"><header class="sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur"><div class="mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8"><a class="flex items-center gap-3" href="/"><img alt="ASX Desk" fetchPriority="high" width="140" height="40" decoding="async" data-nimg="1" class="h-10 w-auto" style="color:transparent" src="/logo.svg"/><span class="hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline">Research Terminal</span></a><nav class="hidden items-center gap-6 text-sm text-slate-300 md:flex"><a class="transition hover:text-white" href="/">Home</a><a class="transition hover:text-white" href="/screener/">Screener</a><a class="transition hover:text-white" href="/sectors/materials/">Sectors</a><a class="transition hover:text-white" href="/news/">News</a><a class="transition hover:text-white" href="/compare/BHP-vs-RIO/">Compare</a><a class="transition hover:text-white" href="/about/">About</a></nav><div class="hidden items-center gap-3 sm:flex"><button class="rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20">Premium Research</button><button class="rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400">Open Account</button></div></div><div class="flex items-center justify-between border-t border-white/5 px-4 py-3 text-xs text-slate-400 md:hidden"><span>AI market insights for ASX investors</span><a class="text-blue-300" href="/screener/">Screener</a></div></header><main class="mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8"><div class="space-y-12"><script type="application/ld+json">{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does EPN do?","acceptedAnswer":{"@type":"Answer","text":"Epsilon Healthcare Limited was primarily involved in the manufacturing and distribution of medicinal cannabis products for the B2B market in Australia, leveraging its TGA-licensed facility in Queensland. However, the company was delisted from the ASX in March 2024 after entering administration."}},{"@type":"Question","name":"Is EPN a good investment?","acceptedAnswer":{"@type":"Answer","text":"As Epsilon Healthcare Limited (EPN) has been delisted from the ASX following its entry into administration, it is no longer an investable company on the public market. Prior to its delisting, it was a highly speculative investment due to its micro-cap status, significant cash burn, and the inherent risks of the nascent medicinal cannabis sector."}},{"@type":"Question","name":"What drives EPN's share price?","acceptedAnswer":{"@type":"Answer","text":"Prior to its delisting, EPN's share price was primarily driven by news related to its financial viability, securing new supply agreements, regulatory approvals for cannabis products, capital raising efforts, and the broader sentiment towards the medicinal cannabis sector. Ultimately, its inability to achieve profitability and manage debt led to its cessation of trading."}}]}</script><section class="grid gap-8 lg:grid-cols-[1.6fr_0.8fr]"><div class="space-y-6"><div class="glass-card rounded-2xl p-6"><p class="text-xs uppercase tracking-[0.3em] text-blue-300">Health Care</p><h1 class="mt-3 font-display text-3xl font-semibold">Epsilon Healthcare Limited<!-- --> (<!-- -->EPN<!-- -->)</h1><p class="mt-4 text-sm text-slate-300">Epsilon Healthcare Limited (EPN) was an Australian pharmaceutical company primarily engaged in the cultivation, manufacturing, and distribution of medicinal cannabis products, focusing on B2B and white-label services. Operating a TGA-licensed facility in Southport, Queensland, the company aimed to supply both domestic and international markets. However, the company faced significant financial challenges, leading to its delisting from the ASX on 1 March 2024 following administration.</p><div class="mt-6 grid gap-4 sm:grid-cols-2"><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-xs text-slate-500">Market Cap</p><p class="mt-2 text-lg font-semibold">A$11M</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-xs text-slate-500">Shares on Issue</p><p class="mt-2 text-lg font-semibold">N/A</p></div></div><div class="mt-6 flex flex-wrap gap-3 text-xs text-slate-400"><a href="" class="rounded-full border border-white/10 px-3 py-1">Company Website</a><span class="rounded-full border border-white/10 px-3 py-1">AI coverage updated hourly</span><span class="rounded-full border border-white/10 px-3 py-1">Data from ASX filings</span></div></div><div class="glass-card rounded-2xl p-6"><h2 class="font-display text-xl font-semibold">Price Chart (TradingView)</h2><div class="mt-4 h-72 rounded-xl border border-dashed border-blue-500/30 bg-ink-900/40 p-6 text-sm text-slate-400">Embed TradingView widget here for <!-- -->EPN<!-- -->. The production version should load live pricing and technical indicators.</div></div><section class="space-y-6"><div class="glass-card rounded-2xl p-6"><h2 class="font-display text-xl font-semibold">AI Analysis</h2><div class="mt-4 space-y-4 text-sm text-slate-300"><p>Prior to its delisting, Epsilon Healthcare&#x27;s business position was characterised by its significant investment in a large-scale medicinal cannabis manufacturing facility and a strategy to become a key B2B supplier. Despite its infrastructure, the company struggled with high operational costs, a competitive market, and challenges in securing sufficient profitable supply agreements, resulting in persistent cash burn and financial distress. Its market capitalisation of A$11M reflected its micro-cap status and the inherent risks associated with early-stage biotech ventures.</p><p>The growth outlook for Epsilon Healthcare as a publicly listed entity is now non-existent due to its delisting and administration. Any &#x27;strategic direction&#x27; or &#x27;upcoming catalysts&#x27; would now be entirely focused on the winding-up process, potential asset sales by administrators, and the resolution of creditor claims, rather than any investment-related growth or operational catalysts for shareholders. Its future, if any, would be under entirely new ownership and structure, not as a publicly traded company on the ASX.</p></div></div><div class="grid gap-6 lg:grid-cols-2"><div class="glass-card rounded-2xl p-6"><h3 class="flex items-center gap-2 text-sm font-semibold text-emerald-300">Bull Case</h3><ul class="mt-4 space-y-2 text-sm text-slate-300"><li>â€¢ <!-- -->Significant growth potential in the global medicinal cannabis market, potentially increasing demand for its B2B manufacturing services.</li><li>â€¢ <!-- -->Leveraging its TGA-licensed, large-scale manufacturing facility to secure high-volume, long-term supply agreements with leading cannabis brands.</li><li>â€¢ <!-- -->Potential for new product development, expansion into higher-margin product categories, or strategic partnerships to enhance revenue streams.</li></ul></div><div class="glass-card rounded-2xl p-6"><h3 class="flex items-center gap-2 text-sm font-semibold text-red-300">Bear Case</h3><ul class="mt-4 space-y-2 text-sm text-slate-300"><li>â€¢ <!-- -->Intense competition, regulatory hurdles, and price compression in the medicinal cannabis sector leading to unsustainable margins and cash burn.</li><li>â€¢ <!-- -->Difficulty in securing and maintaining profitable supply contracts, coupled with high operational expenses for its manufacturing facility.</li><li>â€¢ <!-- -->The ultimate outcome of financial distress, administration, and subsequent delisting from the ASX, resulting in significant loss for shareholders.</li></ul></div></div></section><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Recent Announcements</h3><div class="mt-4 space-y-3 text-sm text-slate-300"><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Epsilon Pharma signs manufacturing agreement with Puro NZ</p><span class="inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400" title="Price sensitive">ðŸš¨ Price Sensitive</span></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>5 Feb 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Progress Report</span></div><p class="mt-2 text-xs text-slate-400">Epsilon Pharma has entered a strategic partnership with Puro NZ to secure its pharmaceutical production capabilities, as detailed in their latest progress report.</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Epsilon Healthcare Awarded Halal Australia Certification</p></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>3 Feb 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Progress Report</span></div></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Quarterly Activities/Appendix 4C Cash Flow Report</p><span class="inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400" title="Price sensitive">ðŸš¨ Price Sensitive</span></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>28 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Quarterly Report</span></div><p class="mt-2 text-xs text-slate-400">Electra Property Trust (EPN) has released its quarterly cash flow report, detailing commitments and financial activities for investors to review.</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Change of Director&#x27;s Interest Notice - Zoe Hutchings</p></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>12 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Director Dealing</span></div></div></div></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">FAQs</h3><div class="mt-4 space-y-3 text-sm text-slate-300"><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">What does EPN do?</p><p class="text-slate-400">Epsilon Healthcare Limited was primarily involved in the manufacturing and distribution of medicinal cannabis products for the B2B market in Australia, leveraging its TGA-licensed facility in Queensland. However, the company was delisted from the ASX in March 2024 after entering administration.</p></div><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">Is EPN a good investment?</p><p class="text-slate-400">As Epsilon Healthcare Limited (EPN) has been delisted from the ASX following its entry into administration, it is no longer an investable company on the public market. Prior to its delisting, it was a highly speculative investment due to its micro-cap status, significant cash burn, and the inherent risks of the nascent medicinal cannabis sector.</p></div><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">What drives EPN&#x27;s share price?</p><p class="text-slate-400">Prior to its delisting, EPN&#x27;s share price was primarily driven by news related to its financial viability, securing new supply agreements, regulatory approvals for cannabis products, capital raising efforts, and the broader sentiment towards the medicinal cannabis sector. Ultimately, its inability to achieve profitability and manage debt led to its cessation of trading.</p></div></div></div></div><div class="space-y-6"><div class="glass-card rounded-2xl p-6"><h3 class="font-semibold">Key Metrics</h3><div class="mt-4 space-y-4 text-sm"><div class="flex items-center justify-between"><span class="text-slate-400">Share Price</span><span class="font-semibold">A$<!-- -->0.03</span></div><div class="flex items-center justify-between"><span class="text-slate-400">1Y Performance</span><span class="font-semibold text-emerald-400">37.5<!-- -->%</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Market Cap</span><span class="font-semibold">A$11M</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Shares on Issue</span><span class="font-semibold">N/A</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Sector</span><span class="font-semibold">Health Care</span></div><div class="flex items-center justify-between"><span class="text-slate-400">IPO Date</span><span class="font-semibold">04/05/2017</span></div></div></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Compare ASX Brokers</h3><p class="mt-2 text-sm text-slate-400">Find the best trading platform for your needs. We review fees, features, and research tools.</p><div class="mt-4 grid gap-3 sm:grid-cols-2"><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-sm font-semibold text-white">AlphaTrade</p><p class="text-xs text-slate-400">$0 brokerage on ETFs</p><button class="mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white">Open an Account</button></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-sm font-semibold text-white">MarketPilot</p><p class="text-xs text-slate-400">Advanced research suite</p><button class="mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white">Open an Account</button></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-sm font-semibold text-white">Coastline</p><p class="text-xs text-slate-400">Low FX fees</p><button class="mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white">Open an Account</button></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-sm font-semibold text-white">Harbour</p><p class="text-xs text-slate-400">Pro-level charting</p><button class="mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white">Open an Account</button></div></div><p class="mt-3 text-xs text-slate-500">Sponsored links. We may receive compensation if you open an account.</p></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Related Stocks</h3><div class="mt-4 space-y-4"><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CSL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CSL<span class="ml-2 text-sm text-slate-400">CSL Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->181.24</p><p class="text-xs font-semibold text-red-400">-27.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$88.2B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PNV/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PNV<span class="ml-2 text-sm text-slate-400">Polynovo Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.99</p><p class="text-xs font-semibold text-red-400">-13.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$670M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/1AD/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">1AD<span class="ml-2 text-sm text-slate-400">Adalta Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-25.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$11M</span><span class="text-blue-300">View analysis</span></div></a></div></div></div></section></div></main><footer class="border-t border-white/10 bg-ink-800/60"><div class="mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8"><div><h3 class="font-display text-lg font-semibold">ASX Desk</h3><p class="mt-3 text-sm text-slate-400">Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools.</p><div class="mt-4 flex gap-3"><button class="rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white">Open an Account</button><button class="rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300">Download Media Kit</button></div></div><div class="grid grid-cols-2 gap-6 text-sm text-slate-400"><div><h4 class="mb-2 font-semibold text-slate-200">Platform</h4><ul class="space-y-2"><li><a class="hover:text-white" href="/screener/">Screener</a></li><li><a class="hover:text-white" href="/news/">News &amp; Commentary</a></li><li><a class="hover:text-white" href="/about/">About</a></li></ul></div><div><h4 class="mb-2 font-semibold text-slate-200">Sectors</h4><ul class="space-y-2"><li><a class="hover:text-white" href="/sectors/materials/">Materials</a></li><li><a class="hover:text-white" href="/sectors/financials/">Financials</a></li><li><a class="hover:text-white" href="/sectors/health care/">Health Care</a></li><li><a class="hover:text-white" href="/sectors/information technology/">Information Tech</a></li><li><a class="hover:text-white" href="/sectors/energy/">Energy</a></li></ul></div></div><div class="glass-card rounded-2xl p-6"><h4 class="font-semibold">Weekly Alpha Briefing</h4><p class="mt-2 text-sm text-slate-400">Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox.</p><div class="mt-4 flex flex-col gap-3 sm:flex-row"><input type="email" placeholder="you@example.com" class="w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"/><button class="rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white">Subscribe</button></div><p class="mt-3 text-xs text-slate-500">By subscribing you agree to receive marketing updates. Unsubscribe anytime.</p></div></div><div class="border-t border-white/10 py-6 text-center text-xs text-slate-500"><p>General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results.</p></div></footer></div><script src="/_next/static/chunks/webpack-27eef1fd2dac2dc4.js" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0]);self.__next_f.push([2,null])</script><script>self.__next_f.push([1,"1:HL[\"/_next/static/media/26d4368bf94c0ec4-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n2:HL[\"/_next/static/media/36966cca54120369-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n3:HL[\"/_next/static/css/115c5e9658b2e8f5.css\",\"style\"]\n"])</script><script>self.__next_f.push([1,"4:I[5751,[],\"\"]\n7:I[231,[\"231\",\"static/chunks/231-13cb1b3c6d429521.js\",\"669\",\"static/chunks/app/asx/%5Bticker%5D/page-f6c15ab6b5482fb0.js\"],\"\"]\n8:I[9275,[],\"\"]\na:I[1343,[],\"\"]\nb:I[8173,[\"231\",\"static/chunks/231-13cb1b3c6d429521.js\",\"410\",\"static/chunks/410-0180f9689c5eaba7.js\",\"185\",\"static/chunks/app/layout-cc68188960cc2107.js\"],\"Image\"]\nd:I[6130,[],\"\"]\n6:T567,{\"@context\":\"https://schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does EPN do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Epsilon Healthcare Limited was primarily involved in the manufacturing and distribution of medicinal cannabis products for the B2B market in Australia, leveraging its TGA-licensed facility in Queensland. However, the company was delisted from the ASX in March 2024 after entering administration.\"}},{\"@type\":\"Question\",\"name\":\"Is EPN a good investment?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As Epsilon Healthcare Limited (EPN) has been delisted from the ASX following its entry into administration, it is no longer an investable company on the public market. Prior to its delisting, it was a highly speculative investment due to its micro-cap status, significant cash burn, and the inherent risks of the nascent medicinal cannabis sector.\"}},{\"@type\":\"Question\",\"name\":\"What drives EPN's share price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Prior to its delisting, EPN's share price was primarily driven by news related to its financial viability, securing new supply agreements, regulatory approvals for cannabis products, capital raising efforts, and the broader sentiment towards the medicinal cannabis sector. Ultimately, its inability to achieve profitability and manage debt led to its cessation of trading.\"}}]}9:[\"ticker\",\"EPN\",\"d\"]\ne:[]\n"])</script><script>self.__next_f.push([1,"0:[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/115c5e9658b2e8f5.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\"}]],[\"$\",\"$L4\",null,{\"buildId\":\"UmLDHh5gfJqJU4XymIubn\",\"assetPrefix\":\"\",\"initialCanonicalUrl\":\"/asx/EPN/\",\"initialTree\":[\"\",{\"children\":[\"asx\",{\"children\":[[\"ticker\",\"EPN\",\"d\"],{\"children\":[\"__PAGE__?{\\\"ticker\\\":\\\"EPN\\\"}\",{}]}]}]},\"$undefined\",\"$undefined\",true],\"initialSeedData\":[\"\",{\"children\":[\"asx\",{\"children\":[[\"ticker\",\"EPN\",\"d\"],{\"children\":[\"__PAGE__\",{},[[\"$L5\",[\"$\",\"div\",null,{\"className\":\"space-y-12\",\"children\":[[\"$\",\"script\",null,{\"type\":\"application/ld+json\",\"dangerouslySetInnerHTML\":{\"__html\":\"$6\"}}],[\"$\",\"section\",null,{\"className\":\"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]\",\"children\":[[\"$\",\"div\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.3em] text-blue-300\",\"children\":\"Health Care\"}],[\"$\",\"h1\",null,{\"className\":\"mt-3 font-display text-3xl font-semibold\",\"children\":[\"Epsilon Healthcare Limited\",\" (\",\"EPN\",\")\"]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-300\",\"children\":\"Epsilon Healthcare Limited (EPN) was an Australian pharmaceutical company primarily engaged in the cultivation, manufacturing, and distribution of medicinal cannabis products, focusing on B2B and white-label services. Operating a TGA-licensed facility in Southport, Queensland, the company aimed to supply both domestic and international markets. However, the company faced significant financial challenges, leading to its delisting from the ASX on 1 March 2024 following administration.\"}],[\"$\",\"div\",null,{\"className\":\"mt-6 grid gap-4 sm:grid-cols-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-500\",\"children\":\"Market Cap\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-lg font-semibold\",\"children\":\"A$11M\"}]]}],[\"$\",\"div\",null,{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-500\",\"children\":\"Shares on Issue\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-lg font-semibold\",\"children\":\"N/A\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"mt-6 flex flex-wrap gap-3 text-xs text-slate-400\",\"children\":[[\"$\",\"a\",null,{\"href\":\"\",\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"Company Website\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"AI coverage updated hourly\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"Data from ASX filings\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"font-display text-xl font-semibold\",\"children\":\"Price Chart (TradingView)\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 h-72 rounded-xl border border-dashed border-blue-500/30 bg-ink-900/40 p-6 text-sm text-slate-400\",\"children\":[\"Embed TradingView widget here for \",\"EPN\",\". The production version should load live pricing and technical indicators.\"]}]]}],[\"$\",\"section\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"font-display text-xl font-semibold\",\"children\":\"AI Analysis\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4 text-sm text-slate-300\",\"children\":[[\"$\",\"p\",\"Prior to its delisting, Epsilon Healthcare's business position was characterised by its significant investment in a large-scale medicinal cannabis manufacturing facility and a strategy to become a key B2B supplier. Despite its infrastructure, the company struggled with high operational costs, a competitive market, and challenges in securing sufficient profitable supply agreements, resulting in persistent cash burn and financial distress. Its market capitalisation of A$11M reflected its micro-cap status and the inherent risks associated with early-stage biotech ventures.\",{\"children\":\"Prior to its delisting, Epsilon Healthcare's business position was characterised by its significant investment in a large-scale medicinal cannabis manufacturing facility and a strategy to become a key B2B supplier. Despite its infrastructure, the company struggled with high operational costs, a competitive market, and challenges in securing sufficient profitable supply agreements, resulting in persistent cash burn and financial distress. Its market capitalisation of A$11M reflected its micro-cap status and the inherent risks associated with early-stage biotech ventures.\"}],[\"$\",\"p\",\"The growth outlook for Epsilon Healthcare as a publicly listed entity is now non-existent due to its delisting and administration. Any 'strategic direction' or 'upcoming catalysts' would now be entirely focused on the winding-up process, potential asset sales by administrators, and the resolution of creditor claims, rather than any investment-related growth or operational catalysts for shareholders. Its future, if any, would be under entirely new ownership and structure, not as a publicly traded company on the ASX.\",{\"children\":\"The growth outlook for Epsilon Healthcare as a publicly listed entity is now non-existent due to its delisting and administration. Any 'strategic direction' or 'upcoming catalysts' would now be entirely focused on the winding-up process, potential asset sales by administrators, and the resolution of creditor claims, rather than any investment-related growth or operational catalysts for shareholders. Its future, if any, would be under entirely new ownership and structure, not as a publicly traded company on the ASX.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"grid gap-6 lg:grid-cols-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"flex items-center gap-2 text-sm font-semibold text-emerald-300\",\"children\":\"Bull Case\"}],[\"$\",\"ul\",null,{\"className\":\"mt-4 space-y-2 text-sm text-slate-300\",\"children\":[[\"$\",\"li\",\"Significant growth potential in the global medicinal cannabis market, potentially increasing demand for its B2B manufacturing services.\",{\"children\":[\"â€¢ \",\"Significant growth potential in the global medicinal cannabis market, potentially increasing demand for its B2B manufacturing services.\"]}],[\"$\",\"li\",\"Leveraging its TGA-licensed, large-scale manufacturing facility to secure high-volume, long-term supply agreements with leading cannabis brands.\",{\"children\":[\"â€¢ \",\"Leveraging its TGA-licensed, large-scale manufacturing facility to secure high-volume, long-term supply agreements with leading cannabis brands.\"]}],[\"$\",\"li\",\"Potential for new product development, expansion into higher-margin product categories, or strategic partnerships to enhance revenue streams.\",{\"children\":[\"â€¢ \",\"Potential for new product development, expansion into higher-margin product categories, or strategic partnerships to enhance revenue streams.\"]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"flex items-center gap-2 text-sm font-semibold text-red-300\",\"children\":\"Bear Case\"}],[\"$\",\"ul\",null,{\"className\":\"mt-4 space-y-2 text-sm text-slate-300\",\"children\":[[\"$\",\"li\",\"Intense competition, regulatory hurdles, and price compression in the medicinal cannabis sector leading to unsustainable margins and cash burn.\",{\"children\":[\"â€¢ \",\"Intense competition, regulatory hurdles, and price compression in the medicinal cannabis sector leading to unsustainable margins and cash burn.\"]}],[\"$\",\"li\",\"Difficulty in securing and maintaining profitable supply contracts, coupled with high operational expenses for its manufacturing facility.\",{\"children\":[\"â€¢ \",\"Difficulty in securing and maintaining profitable supply contracts, coupled with high operational expenses for its manufacturing facility.\"]}],[\"$\",\"li\",\"The ultimate outcome of financial distress, administration, and subsequent delisting from the ASX, resulting in significant loss for shareholders.\",{\"children\":[\"â€¢ \",\"The ultimate outcome of financial distress, administration, and subsequent delisting from the ASX, resulting in significant loss for shareholders.\"]}]]}]]}]]}]]}],null,[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Recent Announcements\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-3 text-sm text-slate-300\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Epsilon Pharma signs manufacturing agreement with Puro NZ\"}],[\"$\",\"span\",null,{\"className\":\"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400\",\"title\":\"Price sensitive\",\"children\":\"ðŸš¨ Price Sensitive\"}]]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"5 Feb 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Progress Report\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-xs text-slate-400\",\"children\":\"Epsilon Pharma has entered a strategic partnership with Puro NZ to secure its pharmaceutical production capabilities, as detailed in their latest progress report.\"}]]}],[\"$\",\"div\",\"1\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Epsilon Healthcare Awarded Halal Australia Certification\"}],false]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"3 Feb 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Progress Report\"}]]}],\"\"]}],[\"$\",\"div\",\"2\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Quarterly Activities/Appendix 4C Cash Flow Report\"}],[\"$\",\"span\",null,{\"className\":\"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400\",\"title\":\"Price sensitive\",\"children\":\"ðŸš¨ Price Sensitive\"}]]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"28 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Quarterly Report\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-xs text-slate-400\",\"children\":\"Electra Property Trust (EPN) has released its quarterly cash flow report, detailing commitments and financial activities for investors to review.\"}]]}],[\"$\",\"div\",\"3\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Change of Director's Interest Notice - Zoe Hutchings\"}],false]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"12 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Director Dealing\"}]]}],\"\"]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"FAQs\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-3 text-sm text-slate-300\",\"children\":[[\"$\",\"div\",\"What does EPN do?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"What does EPN do?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"Epsilon Healthcare Limited was primarily involved in the manufacturing and distribution of medicinal cannabis products for the B2B market in Australia, leveraging its TGA-licensed facility in Queensland. However, the company was delisted from the ASX in March 2024 after entering administration.\"}]]}],[\"$\",\"div\",\"Is EPN a good investment?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Is EPN a good investment?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"As Epsilon Healthcare Limited (EPN) has been delisted from the ASX following its entry into administration, it is no longer an investable company on the public market. Prior to its delisting, it was a highly speculative investment due to its micro-cap status, significant cash burn, and the inherent risks of the nascent medicinal cannabis sector.\"}]]}],[\"$\",\"div\",\"What drives EPN's share price?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"What drives EPN's share price?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"Prior to its delisting, EPN's share price was primarily driven by news related to its financial viability, securing new supply agreements, regulatory approvals for cannabis products, capital raising efforts, and the broader sentiment towards the medicinal cannabis sector. Ultimately, its inability to achieve profitability and manage debt led to its cessation of trading.\"}]]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-semibold\",\"children\":\"Key Metrics\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4 text-sm\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Share Price\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":[\"A$\",\"0.03\"]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"1Y Performance\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold text-emerald-400\",\"children\":[\"37.5\",\"%\"]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Market Cap\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"A$11M\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Shares on Issue\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"N/A\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Sector\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"Health Care\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"IPO Date\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"04/05/2017\"}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Compare ASX Brokers\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-sm text-slate-400\",\"children\":\"Find the best trading platform for your needs. We review fees, features, and research tools.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 grid gap-3 sm:grid-cols-2\",\"children\":[[\"$\",\"div\",\"AlphaTrade\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm font-semibold text-white\",\"children\":\"AlphaTrade\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-400\",\"children\":\"$$0 brokerage on ETFs\"}],[\"$\",\"button\",null,{\"className\":\"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Open an Account\"}]]}],[\"$\",\"div\",\"MarketPilot\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm font-semibold text-white\",\"children\":\"MarketPilot\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-400\",\"children\":\"Advanced research suite\"}],[\"$\",\"button\",null,{\"className\":\"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Open an Account\"}]]}],[\"$\",\"div\",\"Coastline\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm font-semibold text-white\",\"children\":\"Coastline\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-400\",\"children\":\"Low FX fees\"}],[\"$\",\"button\",null,{\"className\":\"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Open an Account\"}]]}],[\"$\",\"div\",\"Harbour\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm font-semibold text-white\",\"children\":\"Harbour\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-400\",\"children\":\"Pro-level charting\"}],[\"$\",\"button\",null,{\"className\":\"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Open an Account\"}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-xs text-slate-500\",\"children\":\"Sponsored links. We may receive compensation if you open an account.\"}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Related Stocks\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4\",\"children\":[[\"$\",\"$L7\",null,{\"href\":\"/asx/CSL\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CSL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"CSL Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"181.24\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-27.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$88.2B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L7\",null,{\"href\":\"/asx/PNV\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PNV\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Polynovo Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.99\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-13.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$670M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L7\",null,{\"href\":\"/asx/1AD\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"1AD\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Adalta Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-25.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$11M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},[\"$\",\"$L8\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"asx\",\"children\",\"$9\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$La\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\",\"styles\":null}],null]},[\"$\",\"$L8\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"asx\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$La\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\",\"styles\":null}],null]},[[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"__variable_6d343d __variable_49a339\",\"children\":[[\"$\",\"head\",null,{\"children\":[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/logo.svg\",\"type\":\"image/svg+xml\"}]}],[\"$\",\"body\",null,{\"className\":\"min-h-screen bg-ink-900 text-slate-100\",\"children\":[\"$\",\"div\",null,{\"className\":\"grid-glow min-h-screen\",\"children\":[[\"$\",\"header\",null,{\"className\":\"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8\",\"children\":[[\"$\",\"$L7\",null,{\"href\":\"/\",\"className\":\"flex items-center gap-3\",\"children\":[[\"$\",\"$Lb\",null,{\"src\":\"/logo.svg\",\"alt\":\"ASX Desk\",\"width\":140,\"height\":40,\"className\":\"h-10 w-auto\",\"priority\":true}],[\"$\",\"span\",null,{\"className\":\"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline\",\"children\":\"Research Terminal\"}]]}],[\"$\",\"nav\",null,{\"className\":\"hidden items-center gap-6 text-sm text-slate-300 md:flex\",\"children\":[[\"$\",\"$L7\",\"/\",{\"href\":\"/\",\"className\":\"transition hover:text-white\",\"children\":\"Home\"}],[\"$\",\"$L7\",\"/screener\",{\"href\":\"/screener\",\"className\":\"transition hover:text-white\",\"children\":\"Screener\"}],[\"$\",\"$L7\",\"/sectors/materials\",{\"href\":\"/sectors/materials\",\"className\":\"transition hover:text-white\",\"children\":\"Sectors\"}],[\"$\",\"$L7\",\"/news\",{\"href\":\"/news\",\"className\":\"transition hover:text-white\",\"children\":\"News\"}],[\"$\",\"$L7\",\"/compare/BHP-vs-RIO\",{\"href\":\"/compare/BHP-vs-RIO\",\"className\":\"transition hover:text-white\",\"children\":\"Compare\"}],[\"$\",\"$L7\",\"/about\",{\"href\":\"/about\",\"className\":\"transition hover:text-white\",\"children\":\"About\"}]]}],[\"$\",\"div\",null,{\"className\":\"hidden items-center gap-3 sm:flex\",\"children\":[[\"$\",\"button\",null,{\"className\":\"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20\",\"children\":\"Premium Research\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400\",\"children\":\"Open Account\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between border-t border-white/5 px-4 py-3 text-xs text-slate-400 md:hidden\",\"children\":[[\"$\",\"span\",null,{\"children\":\"AI market insights for ASX investors\"}],[\"$\",\"$L7\",null,{\"href\":\"/screener\",\"className\":\"text-blue-300\",\"children\":\"Screener\"}]]}]]}],[\"$\",\"main\",null,{\"className\":\"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8\",\"children\":[\"$\",\"$L8\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$La\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[\"$\",\"div\",null,{\"className\":\"flex min-h-[60vh] flex-col items-center justify-center text-center\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.3em] text-blue-300\",\"children\":\"404\"}],[\"$\",\"h1\",null,{\"className\":\"mt-3 font-display text-3xl font-semibold\",\"children\":\"Page not found\"}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-sm text-slate-400\",\"children\":\"We couldn't locate that ASX page. Try searching a ticker or visit the homepage.\"}],[\"$\",\"$L7\",null,{\"href\":\"/\",\"className\":\"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Back to Home\"}]]}],\"notFoundStyles\":[],\"styles\":null}]}],[\"$\",\"footer\",null,{\"className\":\"border-t border-white/10 bg-ink-800/60\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"ASX Desk\"}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-sm text-slate-400\",\"children\":\"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex gap-3\",\"children\":[[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Open an Account\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300\",\"children\":\"Download Media Kit\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"grid grid-cols-2 gap-6 text-sm text-slate-400\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"mb-2 font-semibold text-slate-200\",\"children\":\"Platform\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L7\",null,{\"href\":\"/screener\",\"className\":\"hover:text-white\",\"children\":\"Screener\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L7\",null,{\"href\":\"/news\",\"className\":\"hover:text-white\",\"children\":\"News \u0026 Commentary\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L7\",null,{\"href\":\"/about\",\"className\":\"hover:text-white\",\"children\":\"About\"}]}]]}]]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"mb-2 font-semibold text-slate-200\",\"children\":\"Sectors\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L7\",null,{\"href\":\"/sectors/materials\",\"className\":\"hover:text-white\",\"children\":\"Materials\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L7\",null,{\"href\":\"/sectors/financials\",\"className\":\"hover:text-white\",\"children\":\"Financials\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L7\",null,{\"href\":\"/sectors/health care\",\"className\":\"hover:text-white\",\"children\":\"Health Care\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L7\",null,{\"href\":\"/sectors/information technology\",\"className\":\"hover:text-white\",\"children\":\"Information Tech\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L7\",null,{\"href\":\"/sectors/energy\",\"className\":\"hover:text-white\",\"children\":\"Energy\"}]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h4\",null,{\"className\":\"font-semibold\",\"children\":\"Weekly Alpha Briefing\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-sm text-slate-400\",\"children\":\"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex flex-col gap-3 sm:flex-row\",\"children\":[[\"$\",\"input\",null,{\"type\":\"email\",\"placeholder\":\"you@example.com\",\"className\":\"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Subscribe\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-xs text-slate-500\",\"children\":\"By subscribing you agree to receive marketing updates. Unsubscribe anytime.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"border-t border-white/10 py-6 text-center text-xs text-slate-500\",\"children\":[\"$\",\"p\",null,{\"children\":\"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results.\"}]}]]}]]}]}]]}],null],null],\"couldBeIntercepted\":false,\"initialHead\":[null,\"$Lc\"],\"globalErrorComponent\":\"$d\",\"missingSlots\":\"$We\"}]]\n"])</script><script>self.__next_f.push([1,"c:[[\"$\",\"meta\",\"0\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}],[\"$\",\"meta\",\"1\",{\"charSet\":\"utf-8\"}],[\"$\",\"title\",\"2\",{\"children\":\"EPN share price, analysis \u0026 company profile - Epsilon Healthcare Limited | ASX Desk\"}],[\"$\",\"meta\",\"3\",{\"name\":\"description\",\"content\":\"Latest EPN share price overview, what Epsilon Healthcare Limited does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"link\",\"4\",{\"rel\":\"canonical\",\"href\":\"https://asxdesk.com/asx/EPN/\"}],[\"$\",\"meta\",\"5\",{\"property\":\"og:title\",\"content\":\"EPN share price, analysis \u0026 company profile - Epsilon Healthcare Limited\"}],[\"$\",\"meta\",\"6\",{\"property\":\"og:description\",\"content\":\"Latest EPN share price overview, what Epsilon Healthcare Limited does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"meta\",\"7\",{\"property\":\"og:url\",\"content\":\"https://asxdesk.com/asx/EPN/\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"9\",{\"name\":\"twitter:card\",\"content\":\"summary_large_image\"}],[\"$\",\"meta\",\"10\",{\"name\":\"twitter:title\",\"content\":\"EPN share price, analysis \u0026 company profile - Epsilon Healthcare Limited\"}],[\"$\",\"meta\",\"11\",{\"name\":\"twitter:description\",\"content\":\"Latest EPN share price overview, what Epsilon Healthcare Limited does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"meta\",\"12\",{\"name\":\"next-size-adjust\"}]]\n5:null\n"])</script></body></html>